Drug Absorption Mechanisms and Factors

Introduction to Oral Drug Absorption

Understanding how a drug moves from the gastrointestinal (GI) tract into the systemic circulation is essential for designing effective oral therapies. This course explores the key physicochemical and physiological factors that govern drug dissolution, ionization, absorption pathways, and the Biopharmaceutics Classification System (BCS). By the end of the module, you will be able to predict how changes in formulation or environment influence oral bioavailability.

1. Dissolution Rate – The First Barrier

The dissolution rate determines how quickly a solid drug becomes available for absorption. According to the Noyes‑Whitney equation, the rate is directly proportional to the surface area of the drug particles and the solubility of the compound, and inversely proportional to the diffusion layer thickness. Among the answer choices in the quiz, the factor that most directly increases dissolution is:

• Increasing the drug's ionized fraction at intestinal pH. Ionized molecules are more soluble in the aqueous environment of the GI lumen, accelerating dissolution.

Other options such as a higher partition coefficient or greater lipid solubility improve membrane permeation but do not directly boost the rate at which the solid drug dissolves.

2. The Role of pKa and Ionization

Drug ionization is governed by the Henderson‑Hasselbalch relationship. For an acidic drug (pKa = 2) entering the small intestine (pH ≈ 6), the equation pH = pKa + log([A⁻]/[HA]) predicts a predominance of the ionized form:

• Predominantly ionized (≈99.9% A⁻).

Ionized acids dissolve well but cross lipid membranes less efficiently, highlighting the need for a balance between solubility and permeability.

3. Major Absorption Pathways

Oral drugs can cross the intestinal epithelium via four principal routes:

• Passive transcellular diffusion – driven by the concentration gradient and lipid solubility.
• Paracellular diffusion – movement through tight junctions, limited to small, hydrophilic molecules.
• Carrier‑mediated (facilitated) diffusion – saturable, follows Michaelis‑Menten kinetics.
• Transcytosis (endocytosis/exocytosis) – used for macromolecules and some peptides.

Each pathway has distinct size, charge, and solubility preferences, which are reflected in the quiz questions.

4. Saturable Transport – Carrier‑Mediated Diffusion

When a drug relies on a specific transporter, the rate of absorption can become saturated at high concentrations. This behavior follows the Michaelis‑Menten equation: v = (Vmax·[S])/(Km + [S]). The quiz correctly identifies the saturated pathway as:

• Carrier‑mediated diffusion following Michaelis‑Menten kinetics.

In contrast, passive diffusion and paracellular routes are generally linear with respect to concentration, unless the drug itself alters membrane properties.

5. Biopharmaceutics Classification System (BCS)

The BCS categorises oral drugs based on two parameters: aqueous solubility and intestinal permeability. A drug that is highly lipophilic (high partition coefficient, P) but poorly soluble in water fits the profile of:

• Class II – low solubility, high permeability.

Class II compounds are often dissolution‑limited; formulation strategies such as solid dispersions or nanocrystals are employed to enhance solubility and, consequently, bioavailability.

6. pH Effects on Weak Bases

Weak bases are more ionized in acidic environments and become less ionized as pH rises. The less-ionized form generally crosses lipid membranes more readily, but it is also less soluble in aqueous gastrointestinal fluids.

Increasing gastrointestinal pH can therefore reduce the solubility and dissolution of a poorly soluble weak base. Even though the dissolved, non-ionized fraction may permeate membranes well, less drug may remain available in solution for absorption.

This solubility–permeability trade-off explains why acid-reducing agents can lower exposure to some weak-base drugs; the effect is drug- and formulation-dependent.

7. Anatomical Surface Area – Where Absorption Peaks

The small intestine provides the greatest absorptive surface area due to its length, villi, and microvilli. Quantitatively, the surface area exceeds 200 m², dwarfing the stomach (

• Small intestine.

Formulators often target this region with enteric coatings or site‑specific release systems to maximise exposure.

8. Molecular Size and the Paracellular Route

Paracellular diffusion is restricted to small, hydrophilic molecules that can slip between tight junctions. High‑molecular‑weight drugs are effectively excluded from this pathway. The quiz highlights this limitation:

• Paracellular diffusion is the pathway most likely to be limited for a large molecule.

To bypass this barrier, strategies such as carrier‑mediated transport, pro‑drug design, or nanoparticle carriers are employed.

9. Concentration Gradient and Passive Diffusion Rate

For drugs absorbed by passive diffusion with adequate blood flow, the rate of absorption (J) is described by Fick’s first law: J = P·(Ca – Cv), where P is permeability, Ca the concentration at the absorptive surface, and Cv the venous concentration (often negligible initially). Therefore, the absorption rate is:

• Directly proportional to Ca.

This linear relationship holds until the drug’s solubility or transporter capacity becomes limiting.

10. Integrating the Concepts – Practical Implications

When developing an oral dosage form, consider the following checklist:

• Solubility vs. Permeability: Identify the BCS class early; low‑solubility drugs (Class II) need dissolution‑enhancing techniques.
• Ionization State: Use the Henderson‑Hasselbalch equation to predict the dominant species at intestinal pH; adjust formulation pH or use salts to optimise the balance.
• Transport Pathway: Determine whether the drug can use passive diffusion, requires a carrier, or must be delivered via transcytosis.
• Size Constraints: For high‑molecular‑weight molecules, avoid reliance on paracellular diffusion; explore carrier‑mediated or nanoparticle approaches.
• Surface Area Targeting: Design release profiles that align with the small intestine’s extensive surface area for maximal uptake.
• Concentration Gradient: Formulate to maintain a high luminal concentration without exceeding solubility limits, ensuring a favorable gradient for passive diffusion.

By systematically addressing each factor, formulators can predict and improve oral bioavailability, reducing the need for costly trial‑and‑error experiments.

Key Takeaways

• Dissolution rate is accelerated by increasing the ionized fraction of a drug in the GI lumen.
• Acidic drugs with low pKa become predominantly ionized in the small intestine, enhancing solubility but potentially limiting membrane permeation.
• Carrier‑mediated transport is the only absorptive pathway that can become saturated at high drug concentrations.
• High lipophilicity combined with low aqueous solubility points to a BCS Class II drug.
• Moving from BCS Class III to Class I requires higher intestinal permeability while high aqueous solubility is maintained.
• Raising gastrointestinal pH makes weak bases less ionized; this may improve membrane permeability but reduce aqueous solubility and dissolution.
• The small intestine offers the largest absorptive surface area, making it the primary site for oral drug uptake.
• Large molecules are restricted from paracellular diffusion; alternative pathways must be considered.
• For passive diffusion with good perfusion, the absorption rate scales directly with the luminal concentration (Ca).

Mastering these principles equips healthcare professionals, pharmacists, and drug developers with the insight needed to optimise oral therapy and improve patient outcomes.

Scientific References

• ICH M9, Biopharmaceutics Classification System-Based Biowaivers, adopted by the U.S. Food and Drug Administration.
• StatPearls, Drug Absorption, National Center for Biotechnology Information Bookshelf.